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Abstract
AIM: To investigate the effect of Tenascin C (TNC) on 
the expression of pro-inflammatory cytokines and matrix 
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metalloproteinases in human cardiac myofibroblasts 
(CMF).
METHODS: CMF were isolated and cultured from 
patients undergoing coronary artery bypass grafting. 
Cultured cells were treated with either TNC (0.1 μmol/L, 
24 h) or a recombinant protein corresponding to diffe-
rent domains of the TNC protein; fibrinogen-like globe 
(FBG) and fibronectin type Ⅲ-like repeats (TNⅢ 5-7) 
(both 1 μmol/L, 24 h). The expression of the pro-
inflammatory cytokines; interleukin (IL)-6, IL-1β, TNFα 
and the matrix metalloproteinases; MMPs (MMP1, 2, 3, 
9, 10, MT1-MMP) was assessed using real time RT-PCR 
and western blot analysis.
RESULTS: TNC increased both IL-6 and MMP3 (P  < 
0.01) mRNA levels in cultured human CMF but had no 
significant effect on the other markers studied. The 
increase in IL-6 mRNA expression was mirrored by an 
increase in protein secretion as assessed by enzyme-
linked immunosorbant assay (P  < 0.01). Treating 
CMF with the recombinant protein FBG increased IL-6 
mRNA and protein (P  < 0.01) whereas the recombinant 
protein TNⅢ 5-7 had no effect. Neither FBG nor TNⅢ 
5-7 had any significant effect on MMP3 expression. The 
expression of toll-like receptor 4 (TLR4) in human CMF 
was confirmed by real time RT-PCR, western blot and 
immunohistochemistry. Pre-incubation of cells with TLR4 
neutralising antisera attenuated the effect of both TNC 
and FBG on IL-6 mRNA and protein expression. 
CONCLUSION: TNC up-regulates IL-6 expression 
in human CMF, an effect mediated through the FBG 
domain of TNC and via  the TLR4 receptor.
Key words: Tenascin C; Matrix metalloproteinase; Toll-
like receptor; Interleukin-6; Cardiac fibroblasts
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Tenascin C (TNC) is transiently expressed in 
cardiac tissue following acute myocardial infarction (MI) 
and MI patients with higher serum TNC levels have worse 
long term prognosis. This suggests that TNC is important 
in ventricular remodelling, although a functional role in 
this process is unclear. We report that TNC stimulates 
interleukin-6 synthesis in cardiac myofibroblasts, an 
effect mediated by toll-like receptor 4. As a growing 
body of evidence suggests that prolongation of the 
post-infarction inflammatory response results in worse 
remodelling and dysfunction this important observation 
may in part explain the mechanism by which TNC indu-
ces maladaptive ventricular remodelling following MI.
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INTRODUCTION
A number of cardiac pathologies including acute my­
ocardial infarction (MI), ischaemia/reperfusion (I/R) 
injury, hypertensive heart disease and myocarditis 
are associated with activation of pro­inflammatory 
mediators in the heart. Sustained expression of pro­
inflammatory cytokines such as tumor necrosis factor-α 
(TNFα), interleukin (IL)-1 and IL-6 by infiltrating/
resident inflammatory cells and cardiac fibroblasts is 
associated with increased matrix metalloproteinase 
(MMP) production, adverse cardiac remodelling leading 
to fibrosis, left ventricular (LV) dysfunction and heart 
failure[1]. The mechanisms that drive the inflammatory 
response in the heart are not fully understood.
The matricellular protein Tenascin C (TNC) is an 
extracellular glycoprotein that is highly expressed during 
embryonic development but is absent from healthy 
adult tissue. It is re­expressed in adult tissue during 
wound healing, inflammation and cancer invasion. In 
the adult myocardium TNC is up­regulated in patho­
logical conditions that are closely associated with 
inflammation and extensive tissue remodelling such 
as MI[2], myocarditis[3] and dilated cardiomyopathy[4]. 
TNC is synthesised by interstitial fibroblasts and is up-
regulated by various pro-inflammatory cytokines (e.g., 
IL-1, IL-4, IL-13) and growth factors, as well as by 
oxidative and mechanical stress[5-11]. Evidence suggests 
that TNC may promote wound healing by recruiting 
cardiac myofibroblasts (CMF) during tissue repair[12]. 
However, it may also contribute to adverse ventricular 
remodelling as it can upregulate MMP production leading 
to excessive extracellular matrix (ECM) degradation. This 
in turn could weaken the adhesion of cardiomyocytes to 
the ECM, leading to cardiomyocyte slippage, LV dilation 
and reduction in contractile function[13]. Recent studies 
using synovial fibroblasts demonstrated that TNC was 
an endogenous activator of the toll-like receptor 4 (TLR4) 
pathway in the arthritic joint[14].
TLRs play a key role in driving inflammation and 
ECM turnover. They promote innate and adaptive immu­
ne responses including induction of pro­inflammatory 
cytokines and MMPs[15-18]. TLR4 has been identified on 
cardiac myocytes and TLR4 signalling is involved in the 
expression of cytokines in the myocardium[19-21]. More­
over, the TLR4 signalling pathway has been implicated 
in maladaptive ventricular remodelling[1] and in cardiac 
dysfunction after global I/R[22]. 
In the present study we investigated the effect of 
TNC on IL-6, IL-1β and MMP expression in a key cell 
type involved in the myocardial remodelling process, 
namely the human CMF[23,24]. In particular we investi­
gated the interplay between TNC, TLR4 and the pro-
inflammatory cytokine IL-6.
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MATERIALS AND METHODS
Reagents
All cell culture reagents were purchased from Invitrogen 
(Paisley, Scotland, United Kingdom), except foetal calf 
serum (FCS) which was from Biosera (Ringmer, East 
Sussex, United Kingdom). Native human TNC was obt­
ained from AbD Serotec (#8640-0502, Oxford, United 
Kingdom) and recombinant IL-1α from Life Technologies 
(Paisley, Scotland, United Kingdom). Lipopolysaccha-
ride (LPS) was obtained from Sigma (Poole, United 
Kingdom).
Purification of human TNC
Purified human TNC protein (CC065, Millipore) from the 
human glioma cell line U251 was used in the in vitro 
experiments. Endotoxin levels were measured using 
the ToxinSensor Chromogenic LAL Endotoxin Assay Kit 
(Genscript). The TNC protein was taken through an 
endotoxin removal process using Detoxi­Gel Endotoxin 
Removal Columns (Thermoscientific) following the 
manufacturer’s instructions. Commercial TNC, which 
was initially found to have an LPS concentration of 
approximately 15.8 pg/μg protein by LAL test, was 
column purified and found thereafter to be almost 
devoid of contamination (i.e., < 0.1 pg/μg protein, 
which equates to < 3 pg/mL per reaction). The levels 
of LPS contamination of the TNC recombinant proteins 
[fibrinogen-like globe (FBG) and TNⅢ 5-7] was less 
than 10 pg/mL as described earlier[14]. These levels of 
contamination were more than 300-fold lower than 
that required (i.e., 1 ng/mL) to stimulate IL-6 mRNA 
expression in human CMF. Nevertheless, polymyxin B 
was added in our experiments to block the biological 
effects of LPS. There was no evidence that polymyxin B 
alone could trigger IL-6 mRNA expression.
Recombinant TNC fragments
Recombinant TNC fragments corresponding to the FBG 
and fibronectin type Ⅲ-like repeats (TNⅢ 5­7) regions 
of the TNC protein were synthesised and purified as 
described previously[14]. 
Cell culture
Right atrial appendage biopsies from patients undergoing 
elective coronary artery bypass surgery at the Leeds 
General Infirmary were obtained following local ethical 
committee approval (reference number: 01/040) and 
informed patient consent. All investigations conformed 
to the principles outlined in the Declaration of Helsinki, 
1997. Human cardiac fibroblasts were harvested, 
characterised and cultured as we have previously des­
cribed[25,26]. Cells exhibit a myofibroblast phenotype 
as determined by positive staining for both α­smooth 
muscle actin and vimentin at passage 1 through to at 
least passage 5[26]. Experiments were performed on 
cells from passage 3­5 obtained from multiple donors. 
Cells were serum starved for 24 h before performing 
experiments in basal medium (DMEM) supplemented 
with 0.4% FCS and polymyxin B (50 μg/mL), an LPS 
neutralising agent, to ensure that any residual LPS in 
the TNC could not elicit a signal. Cells were treated with 
either IL-1α (10 ng/mL, 24 h), TNC (0.1 μmol/L, 24 h) 
or TNC recombinant fragments (FBG, TNIII 5-7, 1 μmol/L, 
24 h). Concentrations and time point were based on 
preliminary dose response and time course experiments 
(data not shown). In TLR4 neutralising experiments, 
cells were pre-treated with TLR4 neutralising antibody 
(25 μg/mL, #AF1478, R and D Systems, Minneapolis, 
United States) for 1 h prior to TNC addition. 
Quantitative RT-PCR
Cellular RNA was extracted from cells at the end of the 
incubation period and cDNA was prepared as described 
previously[27]. Real time RT­PCR was performed in 
duplicate using the Applied Biosystems 7500 Real-Time 
PCR System. Intron spanning primers and Taqman 
probes for human IL-1β (Hs00174097_m1), IL-6 
(Hs00174131_m1), TNFα (Hs00174128_m1), MMP-1 
(Hs00233958_m1), MMP-2 (Hs00234422_m1), MMP-3 
(Hs00233962_m1), MMP-9 (Hs00234579_m1), MMP-10 
(Hs00233987_m1), MT1-MMP (Hs00237119_m1), 
TLR2 (Hs01872448_s1) and TLR4 (Hs00152939_m1) 
were from Applied Biosystems (www.appliedbiosystems.
com). Data are presented as a relative percentage of 
expression of the endogenous control GAPDH (Hs999-
99905_m1 primers) using the formula 2-∆CT × 100 in 
which CT is the cycle threshold number.
Real time RT-PCR array for TLR expression
RNA was extracted from human CMF from 3 different 
donors using the Aurum Total RNA kit (BioRad). 
Equivalent RNA samples from each of the 3 donors were 
pooled before preparing cDNA and measuring expression 
levels of TLRs as part of a SYBR Green-based real-time 
PCR array (RT2 Profiler Human Innate and Adaptive 
Immune Response Array, SABiosciences, Qiagen). ∆
CT values for the target genes were calculated by 
subtracting the mean CT value (threshold cycle number) 
of the 5 housekeeping (HK) genes on the array (β2­
microglobulin, hypoxanthine phosphoribosyltransferase 
1, ribosomal protein L13A, β­actin and GAPDH) from the 
CT value of the target genes. Data are expressed relative 
to the mean of HK genes using the formula 2-∆CT. 
Western blot analysis for TLR4
Whole cell homogenates were prepared from human 
CMF and cultured human saphenous vein smooth 
muscle cells, as described previously[28]. Proteins (10 
μg) were resolved by SDS­PAGE and immunoblotting 
performed as described previously[28] with TLR4-specific 
primary antibody raised in rabbit (#sc10741, Santa 
Cruz Biotechnology, CA, United States) and horseradish 
peroxidase-conjugated donkey anti-rabbit secondary 
antibody (#NA934V, GE Health Care, United Kingdom). 
Immunolabelled bands were visualised on X-ray film by 
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Multiplex Double Stain Detection Kit 2 (A.MENARINI 
Diagnostics, Berkshire, United Kingdom) and a Mouse 
on Mouse Polymer IHC Kit (Abcam, Cambridge, United 
Kingdom). Sections were also stained for α smooth 
muscle actin (clone 1A4, code no. M851; Dakopatts, 
Glostrup, Denmark) and TLR4 in similar fashion. Tis-
sue sections were counterstained with haematoxylin 
and imaged using an Axioplan Zeiss microscope and 
AxioVision 4.8 software (Carl Zeiss Inc.).
Statistical analysis
Results are mean ± SEM with n representing the 
number of experiments on cells from different pati­
ents. Data were analysed using the student’s t­test or 
repeated measures one-way ANOVA and Bonferroni 
multiple comparison post hoc test (GraphPad Prism 
software, www.graphpad.com). P < 0.05 was considered 
statistically significant. The statistical methods of this 
study were reviewed by Dr. Emma Spary from the 
University of Leeds.
RESULTS
Increased expression of TNC and TLR4 in the infarcted 
ventricle
Three days following LAD ligation, in an experimental 
mouse model of MI, positive interstitial TNC imm­
unoreactivity (brown) was observed in the infarcted 
side of the left ventricle but not in the remote non­
infarcted regions (Figure 1A and D). Light diffuse TLR4 
staining (pink) was noted throughout the myocardium 
on myocytes and interstitial cells (Figure 1D). On the 
infarcted side the TLR4 staining was more evident with 
scattered foci of intense staining visible on myocytes, a 
feature consistent with previous reports[11] as well as on 
CMF (Figure 1B and C). 
TNC up-regulates IL-6 mRNA and protein expression in 
human CMF
To determine whether TNC could stimulate MMP or pro­
inflammatory cytokine synthesis in vitro, human CMF 
were incubated with TNC (0.1 μmol/L TNC or vehicle for 
24 h) and mRNA levels were assessed using RT­PCR. 
A significant increase (14 fold, P < 0.01) in IL-6 mRNA 
expression from basal levels was observed in response 
to TNC (Figure 2). TNC also induced an approximately 
25­fold increase in MMP3 levels (P < 0.01), whereas 
neither IL-1β nor any of the other MMPs analysed by 
real-time RT-PCR showed significant changes in mRNA 
expression in response to TNC (Figure 2). Basal TNFα 
mRNA expression in human CMF was minimal (0.002% 
GAPDH) and TNC had no effect on its expression (data 
not shown).
TLR4 is expressed in human CMF
We examined the mRNA expression of TLR4 in human 
CMF by RT-PCR and TLR4 protein by both western blot 
analysis and immunocytochemistry. Real­time RT­PCR 
SuperSignal West Pico chemiluminescence kit (Perbio, 
Cramlington, United Kingdom).
Enzyme-linked immunosorbant assay
Cells cultured in 48-well plates were serum-starved for 
48 h before exposure to appropriate stimuli for 24 h in 
a volume of 0.25 mL. Conditioned media were collected 
and centrifuged to remove cellular debris, and samples 
were stored at -40 ℃ for subsequent analysis. Enzyme­
linked immunosorbant assay for IL-6 was performed 
according to the manufacturer’s instructions (R and D 
Systems, Abingdon, United Kingdom) using samples 
diluted 1:100.
Immunocytochemistry for TLR4
Human CMF were fixed in paraformaldehyde (40 g/L) 
before permeabilising with Triton X-100 (1 mL/L) in 
PBS. Cells were blocked with bovine serum albumin 
and incubated with goat primary antibody to human 
TLR4 (sc-8694, Santa Cruz Biotechnology, CA, United 
States) followed by Cy3-conjugated donkey anti-
goat secondary antibody (1:1000, Stratech Scientific, 
Soham, Cambridgeshire, United Kingdom). Labelled 
cells were visualised using a Zeiss Imager. Z1 Apotome 
microscope and Axiovision image analysis software 
(Zeiss, Hamburg, Germany). Cells were mounted in 
Vectashield with DAPI (H-1200, Vector Laboratories, CA, 
United States). Antibody specificity was confirmed by 
pre-absorption of primary antibody with TLR4 protein 
(8 μg/mL for 24 h, sc-8694P, Santa Cruz Biotechnology, 
CA, United States). 
MI model 
All procedures involving animals were carried out in 
accordance with the Home Office Animals (Scientific 
Procedures) Act 1986 and the University of Leeds 
Animal Welfare and Ethical Committee. Experiments 
were performed on C57BL/6 mice (25-30 g, University 
of Leeds). Animals were maintained at 22 ℃ on a 
12 h light and dark cycle with ad libitum access to 
food and water. The animal protocol was designed to 
minimise pain or discomfort to the animal. Mice were 
anaesthetised with isofluorane. Under a dissecting 
microscope, a left thoracotomy was performed at the 
level of the 4th intercostal space to allow the left anterior 
descending coronary artery to be visualised. This was 
ligated at the edge of the left atrium with 8-0 prolene 
suture. Occlusion was confirmed by observation of 
pallor of the anterior wall of the LV. 
TNC, TRL4 and α -smooth muscle actin 
immunohistochemistry
Three days following MI, animals were perfused with for­
maldehyde, hearts were removed and wax­embedded. 
Tissue sections (3 μm) were cut and stained for both 
TNC (10337, Immuno-Biological Laboratories Co. Ltd, 
Japan) and TLR4 (sc-10741, Santa Cruz Biotechnology, 
CA, United States) using the MenaPath X­Cell Plus 
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array analysis of TLRs 1-9 revealed that TLR4 was by far the most highly expressed TLR in human CMF at 
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Figure 1  Tenascin C and toll-like receptor 4 staining in the murine left ventricle following infarction. A: Low power view of the infarcted mouse LV showing 
the proximity of TNC (brown) and TLR4 (pink) 3 d following the occlusion of the left anterior coronary artery; B: Diffuse TLR4 staining (open arrows) in myocytes and 
interstitial cells and intense TLR4 staining (solid arrows) in some myocytes. Interstitial TNC staining (brown) is evident around these cells; C: High powered view 
of TLR4 (pink) and alpha smooth muscle actin (brown) staining of cells in the infarcted LV. Intense TLR4 staining can be seen in some myocytes (solid arrow) with 
more diffuse staining seen in some cardiac myofibroblasts (labelled both pink and brown, open arrow); D: Low power view of the non-infarcted side of the mouse 
myocardium stained for TNC (brown) and TLR4 (pink). An absence of TNC staining and light diffuse TLR4 staining of the cells is observed. Inset image: a high 
powered view of cells in this area. In each image cell nuclei were stained with Mayer’s Haematoxylin. RV: Right ventricle. LV: Left ventricle; TNC: Tenascin C; TLR4: 
Toll-like receptor 4.
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Figure 2  Changes in cytokine and matrix metalloproteinase mRNA expression in human cardiac myofibroblasts following incubation with Tenascin C. 
Effect of Tenascin C (TNC) (0.1 μmol/L, 24 h) on MMP1, MMP2, MMP3, MMP9, MMP10, MT1-MMP, IL-1β and IL-6 mRNA expression was assessed in human cardiac 
myofibroblasts (n = 4-6 donors). A significant increase in the expression of MMP3 and IL-6 was observed. Data are expressed as mean ± SEM. bP < 0.01 vs vehicle 
(student’s t-test). MMP: Matrix metalloproteinase; IL: Interleukin.
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the mRNA level (Figure 3A). Lower levels of TLR6 > 
TLR3 > TLR7 > TLR1 were also observed, but TLR2 
was not detected. Follow­up studies with Taqman 
RT­PCR (different primers) on cells from a further 4 
donors confirmed the TLR4 and TLR2 data (Figure 
3B). Western blot analysis revealed a single 95 kDa 
band corresponding to TLR4 in protein lysates isolated 
from human CMF from 4 different donors (Figure 3C). 
Immunocytochemistry with primary antibodies directed 
against human TLR4 revealed a pattern of punctate 
staining in the cytoplasm and nucleus of human CMF 
(Figure 3D1). Staining was not evident if the primary 
antibody was pre-incubated with TLR4 protein (Figure 
3D2). To assess the effect of inflammatory cytokines on 
TLR4 mRNA expression, human CMF were incubated 
with IL-1α. Real-time RT-PCR analysis of TLR4 revealed 
a 2.5 fold increase of expression after 6 h of treatment, 
falling back towards basal levels after 24 h (Figure 3E).
TLR4 mediates TNC up-regulation of IL-6 in human CMF
To determine whether the effects of TNC on IL-6 mRNA 
expression in human CMF were mediated by TLR4, 
cells from 5 donors were pre-incubated with TLR4 
neutralising antibodies prior to TNC treatment (100 
nmol/L, 24 h). TLR4 neutralisation had no significant 
effect on basal IL-6 mRNA expression but did prevent 
TNC-stimulated expression of IL-6 (Figure 4A). These 
changes in IL-6 mRNA expression were mirrored by 
changes in IL-6 protein secretion (Figure 4B). The 
specificity of the TLR4 antisera for the TLR4 receptor 
in our in vitro studies was confirmed by demonstrating 
that pre-treating cells with TLR4 neutralising antibo-
dies had no effect on the IL-1α induced IL-6 mRNA 
expression (Figure 4C). 
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Figure 3  Toll-like receptor 4 expression in human cardiac myofibroblasts. A: Data from RT-PCR array showing abundance of TLR mRNA in a pooled sample of 
human CMF (n = 3 donors). Data expressed relative to 5 housekeeping genes; B: Taqman RT-PCR analysis of TLR2 and TLR4 mRNA levels in human CMF (n = 4 
donors). Note log scale. bP < 0.001 (paired t-test); C: Western blot of CMF homogenates from 4 donors probed with anti-TLR4 antibody. Fifteen micrograms protein 
per lane. Molecular size (kDa) on left. TLR4 = 95 kDa; D1: Immunocytochemical localisation of TLR4 in human CMF using a primary antibody to human TLR4 and a 
Cy3-conjugated secondary antibody; D2: Effect of pre-absorption of primary antibody with TLR4 peptide (8 μg/mL) prior to immunostaining. Nuclei are labelled with 
DAPI. Loss of immunostaining confirms specificity of the antibody. Scale bar 50 μm; E: Effect of IL-1α (10 ng/mL, 6 and 24 h) on TLR4 mRNA expression in human 
CMF (n = 4 donors). Data are expressed as mean ± SEM. dP < 0.01 vs vehicle (ANOVA post-hoc). TLR: Toll-like receptor.
Maqbool A et al . TNC upregulates IL-6 expression in human CMF via  TLR4
346
FBG domain upregulates IL-6 mRNA expression in 
human CMF
Previous studies have implicated the FBG domain of 
TNC in the promotion of cytokine production in synovial 
fibroblasts[14]. To determine whether a similar effect 
was evident in human CMF, cells were incubated with 
recombinant FBG protein (1 μmol/L, 24 h) and IL-6 
mRNA expression assessed. FBG induced a 6-fold 
increase in IL-6 mRNA expression (P < 0.01), whereas 
incubation with the TNⅢ 5­7 recombinant TNC fragment 
had no effect, endorsing the suggestion that the FBG 
domain was crucial for promoting IL-6 production (Figure 
5A). Neither FBG nor TNⅢ 5­7 recombinant proteins 
significantly increased MMP-3 expression in human CMF 
(Figure 5B).
TLR4 mediates FBG up-regulation of IL-6 in human CMF 
To determine whether the effects of FBG on IL-6 mRNA 
expression in human CMF were mediated by TLR4 
pathways, cells from 3 donors were pre­incubated with 
TLR4 neutralising antibodies prior to FBG treatment (1 
μmol/L, 24 h). TLR4 antibodies had no significant effect 
on basal IL-6 mRNA expression but did prevent FBG 
-stimulated expression of IL-6 (Figure 5C).
DISCUSSION
The main finding of the present study is that TNC up-
regulates IL-6 expression in human CMF and that this 
effect is mediated through its FBG domain and the TLR4 
receptor. 
Inflammation and matrix turnover are important 
features in cardiac remodelling post infarction. If 
unchecked, these can lead to chronic maladaptive LV 
remodelling, characterised by progressive ventricular 
dilatation, myocardial hypertrophy, fibrosis, cardiac 
dysfunction and failure. TNC is an ECM glycoprotein 
that is re­expressed in the heart under pathological 
conditions such as MI[29,30], myocarditis[3,31,32] and dilated 
cardiomyopathy[4,33] and is closely associated with tissue 
injury and inflammation[3,31,34]. Following MI, TNC has 
been reported to appear during the acute stage at the 
interface between the infarcted and intact myocardium 
where tissue remodelling is at its most active[2]. There 
is evidence that TNC is a sensitive marker for active 
inflammation in acute myocarditis[3]. Moreover, serum 
levels of TNC correlate with the severity of heart failure, 
LV dysfunction and remodelling in patients with dilated 
cardiomyopathy[35]. These observations suggest that 
TNC expression is maintained in cardiac pathologies in 
which there is ongoing inflammation and remodelling. 
We previously reported that IL-1α up­regulates TNC 
expression in human CMF[11]. IL-1 has been identified 
as one of the initial stimuli that drive the acute inflam-
matory response following MI[36-39]. Increased levels 
of IL-1 have also been implicated in the inflammatory 
response and adverse LV remodelling seen in heart 
failure[40]. The observation that TNC up-regulates IL-6 
expression in our present study supports the previous 
notion that after its initial induction TNC could drive the 
inflammatory response further[14]. 
IL-6 has previously been shown to have important 
roles in inflammation and remodelling in the heart 
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Figure 4  Tenascin C upregulates interleukin-6 expression in human 
cardiac myofibroblasts via toll-like receptor 4. A and B: Effect of TNC (0.1 
μmol/L, 24 h) with and without 1 h pre-incubation in TLR4 antisera (25 μg/mL) 
on IL-6 mRNA (A) and IL-6 protein expression (B) in CMF (4-5 donors). Data 
expressed as mean ± SEM. bP < 0.01 vs vehicle (ANOVA post-hoc). TNC: 
Stimulation with TNC alone; TLR4-Ab: Pre-incubation with TLR4 neutralising 
antisera; TNC/TLR4-Ab: Stimulation with TNC following TLR4 pre-incubation; 
C: Effect of 1 h pre-incubation in TLR4 antisera (25 μg/mL) on IL-1α (10 ng/mL, 
24 h)-stimulated IL-6 mRNA expression in CMF (n = 3 donors). The TLR4 
neutralising antisera had no effect on IL-1α induced IL-6mRNA expression. 
Data expressed as mean ± SEM. dP < 0.0001 vs vehicle (ANOVA post-
hoc). IL-1: Stimulation with IL-1α alone; TLR4-Ab: Pre-incubation with TLR4 
neutralising antisera; IL-1/TLR4-Ab: Stimulation with IL-1α following TLR4 pre-
incubation; TNC: Tenascin C; CMF: Cardiac myofibroblasts; IL: Interleukin; 
TLR: Toll-like receptor.
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following injury by promoting leukocyte infiltration and 
activation, and by modulating fibroblast function[23,41-43]. 
In addition to its pro­inflammatory and fibrogenic 
properties, there is also evidence that IL-6 regulates 
ECM remodelling by enhancing cardiac fibroblast MMP 
expression and modulating tissue inhibitor of MMPs 
(TIMP) expression levels[23,42,44]. Our observations are 
consistent with a previous report in synovial fibroblasts, 
where an up-regulation of IL-6 expression following TNC 
stimulation was purported to play a role in the chronic 
inflammatory response seen in the arthritic joint[14]. 
In that study, the TLR4 pathway was identified as a 
mediator of this effect with the TLR4 receptor being 
activated by the FBG domain of TNC. Importantly, 
our study suggests that this notable mechanism may 
also play a role in the inflammatory response in the 
heart. As TLR4 signalling has long been implicated in 
a range of cardiac pathologies, the confirmation of 
such a mechanism in cardiac cells contributes to our 
understanding of the process of inflammation that 
occurs in the heart.
A regulatory role for TLR4 signalling in inflamm-
ation and ECM turnover has been established and its 
involvement in post­infarct maladaptive remodelling in 
the heart has been reported[1]. Moreover, TLR4 signalling 
has been implicated in myocarditis[45] and in the 
myocardial inflammatory response following regional 
or global ischemia/reperfusion[20,22,46,47]. Although TLR4 
signalling contributes to cardiac dysfunction after MI in 
part through its influence on myocardial production of 
cytokines, the mechanism by which TLR4 is activated 
in these circumstances remains to be defined[22]. 
Evidence that TNC is up­regulated following oxidative 
stress suggests it may be a candidate ligand respon­
sible for TLR4 signalling following ischemic injury[48]. 
Furthermore, our observations that the inflammatory 
cytokine, IL-1α, upregulates both TNC[11] and TLR4 
expression (Figure 3E) in CMF and that both TNC and 
TLR4 are upregulated in the infarcted ventricle (Figure 
1) lends support to their involvement in the cardiac 
inflammatory response following MI[2,14,49].
With the exception of MMP3, neither IL-1β nor any 
of the MMPs analysed by real­time RT­PCR showed 
significant changes in mRNA expression in response 
to TNC. In the case of MMP3, although a significant 
increase from basal expression was indeed observed 
with TNC, the mean induced MMP3 levels were only 
0.05% that of the HK gene GAPDH. Nevertheless, 
this is equivalent to the mRNA level observed in 
response to a low concentration of IL-1 (0.1 ng/mL) in 
these cells which resulted in detectable MMP3 protein 
secretion[50]. We found no evidence, however, that FBG 
was responsible for the increase in MMP3 observed. 
The possibility that a different domain of this molecule, 
other than FBG or TNⅢ5­7, plays a role in MMP3 
induction remains to be tested. Moreover, the recent 
demonstration that some of the effects of TNC are 
mediated via αVβ3 integrin, suggests that the induction 
of MMP3 by TNC may occur via a different receptor 
subtype[51].
The up­regulation of MMP3 by TNC would be consi­
stent with TNC’s role in the degradation of ECM following 
MI and the promotion of a de­adhesive state that 
facilitates migration of fibroblasts and other granulation 
tissue cells to the site of injury[52]. TNC has previously 
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Figure 5  Fibrinogen-like globe domain of Tenascin C up-regulates 
interleukin-6 mRNA expression in human cardiac myofibroblasts via 
toll-like receptor 4. A and B: Effect of 1 μmol/L (24 h) recombinant protein, 
corresponding to either the FBG domain or the fibronectin type III domain (TNIII 
5-7) of TNC, on IL-6 mRNA (A) and MMP3 mRNA (B) in human CMF (n = 3-5 
donors). Data expressed as mean ± SEM. bP < 0.01 vs vehicle (ANOVA post-
hoc); C: Effect of 1 h pre-incubation in TLR4 neutralising antisera (25 μg/mL) 
alone on IL-6 mRNA expression and on FBG (1 μmol/L, 24 h) stimulated IL-6 
mRNA expression in CMF (n = 3 donors). Data expressed as mean ± SEM. bP 
< 0.01 vs vehicle (ANOVA post-hoc). FBG: Stimulation with FBG recombinant 
alone; TLR4-Ab: Pre-incubation with TLR4 neutralising antisera; FBG/TLR4-Ab: 
Stimulation with FBG following pre-incubation with TLR4 neutralising antisera. 
FBG: Fibrinogen-like globe; TNC: Tenascin C; IL: Interleukin; CMF: Cardiac 
myofibroblasts.
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been reported to induce cell-specific increases in MMP 
levels including cultured human smooth muscle cells, 
murine mammary cancer cells, macrophages and 
synovial fibroblasts[53-56]. 
Finally, the lack of induction of IL-1β and TNFα by 
TNC is consistent with previous studies which have 
reported that stimulation of synovial fibroblasts with 
TNC resulted in augmented gene expression of some 
pro-inflammatory cytokines (e.g., IL-1α and IL-6), but 
not others (e.g., interferon­γ, TNF­α and IL-1β)[14,56]. 
In conclusion, we have demonstrated that TNC up­
regulates MMP3 and the pro-inflammatory cytokine 
IL-6 in human CMF. The latter effect of TNC is mediated 
via the TLR4 receptor and the FBG domain of the TNC. 
Targeting the FBG domain of TNC may provide a novel 
therapeutic option to counteract aberrant inflammation 
and maladaptive cardiac remodelling.
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